top of page

FREE Biopharma Daily Stock Updates - 02/17/21

Want to access our searchable database of catalysts and companies? Get access to BiopharmIQ for 30 days free, no credit card required. Check it out here!


$XBI $160.72 +1% 📈

Covid Updates

$RDHL +4% First patient dosed in ph 2/3 study of RHB-107. source

Pipeline Updates

$NKTR +13% Collaboration with SFJ Pharma for up to $150M to support registrational phase 2/3 trial of BEMPEG + KEYTRUDA in patients with head and neck cancer whose tumors express PD-L1. source

$VTVT +7% Phase 1 initiation of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis. source

$MYOV +4% Phase 3 LIBERTY study of Relugolix published in NEJM. source

$BPMC +8% sNDA accepted accepted for AYVAKIT for advanced systemic mastocytosis (SM). The FDA granted priority review and set a PDUFA target action date of June 16, 2021. source

Financial Updates

$MTEM -1% Offering

$YMAB -9% Offering

bottom of page